Gland Pharma's Q2 FY 2025-26 Quarterly Results

Result Summary

• Gland Pharma Ltd reported a 0.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 7.2%.
• Its expenses for the quarter were up by 2.9% QoQ and 6.5% YoY.
• The net profit decreased 14.8% QoQ and increased 12.3% YoY.
• The earnings per share (EPS) of Gland Pharma Ltd stood at 11.15 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Gland Pharma Ltd is a pharmaceutical company known for its development, manufacturing, and marketing of complex injectables. The company primarily serves the generic injectable market, focusing on critical care and chronic therapeutic areas. Gland Pharma operates in a highly regulated industry, with exports contributing significantly to its revenue, particularly in the United States, Europe, Canada, Australia, and India. Recent developments in the company, if any, are not provided in the current dataset. The company has a robust manufacturing base with facilities approved by major regulatory agencies, such as the US FDA.

Revenue

In Q2FY26, Gland Pharma Ltd reported a total income of ₹1571.04 crores, reflecting a quarter-over-quarter (QoQ) increase of 0.5% compared to ₹1563.15 crores in Q1FY26. Year-over-year (YoY) growth was more significant, with a 7.2% increase from ₹1465.49 crores in Q2FY25. This consistent growth in revenue indicates a stable performance in terms of income generation over the quarters and years under comparison. The company’s ability to maintain an upward trajectory in revenue highlights its capacity to sustain its operations effectively in the competitive pharmaceutical market.

Profitability

Gland Pharma Ltd's profitability showcased some fluctuations in the reported quarter. The profit before tax (PBT) for Q2FY26 was ₹283.92 crores, which marked a decrease of 9.2% QoQ from ₹312.74 crores in Q1FY26. However, when compared to Q2FY25, there was a YoY increase of 10.6% from ₹256.78 crores. The profit after tax (PAT) followed a similar trend, with Q2FY26 figures standing at ₹183.68 crores, a 14.8% decrease QoQ from ₹215.48 crores in Q1FY26, but a 12.3% increase YoY from ₹163.53 crores in Q2FY25. The Earnings Per Share (EPS) mirrored the PAT, standing at ₹11.15 in Q2FY26, down from ₹13.08 in the previous quarter but up from ₹9.93 in the same quarter last year.

Operating Metrics

The total expenses for Gland Pharma Ltd in Q2FY26 were ₹1287.12 crores, which represents a QoQ increase of 2.9% from ₹1250.41 crores in Q1FY26 and a YoY increase of 6.5% from ₹1208.72 crores in Q2FY25. The tax expense for the quarter was ₹100.23 crores, showing a 3.1% increase QoQ from ₹97.26 crores in Q1FY26 and a 7.5% increase YoY from ₹93.25 crores in Q2FY25. These metrics indicate a rise in the company's operational costs and tax liabilities over the periods considered. However, specific financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio cannot be calculated from the provided data, as these require additional information like market capitalization, total debt, total equity, and current assets and liabilities.